We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+20.62%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$954M
AUM Growth
+$107M
Cap. Flow
-$48.6M
Cap. Flow %
-5.1%
Top 10 Hldgs %
71.6%
Holding
36
New
4
Increased
11
Reduced
10
Closed
2

Top Buys

Rank Stock Value
1
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
+$31M
2
ITMN
INTERMUNE INC
ITMN
+$25.5M
3
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$15.6M
4
UTHR icon
United Therapeutics
UTHR
+$11.9M
5
EXAS
Exact Sciences
EXAS
+$10M

Top Sells

Rank Stock Value
1
ONXX
ONYX PHARMACEUTICALS INC
ONXX
+$124M
2
VPHM
VIROPHARMA INC
VPHM
+$28.6M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$14.8M
4
AEGR
Aegerion Pharmaceuticals
AEGR
+$3.11M
5
QCOR
QUESTCOR PHARMA INC
QCOR
+$2.4M

Sector Composition

Rank Sector Weight
1 Healthcare 36.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VPHM
1
DELISTED
VIROPHARMA INC
VPHM
$121M 12.73%
3,093,291
-875,527
-22% -$28.6M
CYBX
2
DELISTED
CYBERONICS INC
CYBX
$97.4M 10.21%
1,919,518
+56,400
+3% +$2.96M
UTHR icon
3
United Therapeutics
UTHR
$23.1B
$83.9M 8.79%
1,063,442
+162,664
+18% +$11.9M
AUXL
4
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$83.1M 8.7%
4,563,520
+1,715,678
+60% +$31M
CBST
5
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$64.5M 6.76%
1,014,611
+257,790
+34% +$15.6M
ITMN
6
DELISTED
INTERMUNE INC
ITMN
$55.3M 5.8%
3,595,756
+1,820,271
+103% +$25.5M
ABMD
7
DELISTED
Abiomed Inc
ABMD
$50.6M 5.3%
2,654,347
+334,949
+14% +$7.66M
STAA icon
8
STAAR Surgical
STAA
$1.21B
$43.5M 4.56%
3,211,318
– –
ONXX
9
DELISTED
ONYX PHARMACEUTICALS INC
ONXX
$42.8M 4.49%
343,473
-981,642
-74% -$124M
BMRN icon
10
BioMarin Pharmaceuticals
BMRN
$12.4B
$40.7M 4.27%
564,287
-222,832
-28% -$14.8M
QCOR
11
DELISTED
QUESTCOR PHARMA INC
QCOR
$38M 3.99%
655,997
-40,300
-6% -$2.4M
AMAG
12
DELISTED
AMAG Pharmaceuticals
AMAG
$36.8M 3.86%
1,715,377
+34,506
+2% +$815K
VNDA icon
13
Vanda Pharmaceuticals
VNDA
$302M
$31.8M 3.34%
2,908,314
+526,438
+22% +$5.62M
RIGL icon
14
Rigel Pharmaceuticals
RIGL
$750M
$22.6M 2.36%
629,966
+236,408
+60% +$8.63M
SQNM
15
DELISTED
SEQUENOM INC NEW
SQNM
$21.9M 2.3%
8,202,254
-438
-0% -$1.47K
ANAC
16
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$17M 1.78%
1,600,178
-17,473
-1% -$153K
MNTA
17
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$16.4M 1.71%
1,136,676
-38,400
-3% -$588K
KYTH
18
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$14.5M 1.52%
319,113
+232,912
+270% +$6.97M
ALIM
19
DELISTED
Alimera Sciences
ALIM
$13.7M 1.43%
242,332
– –
FOLD
20
DELISTED
Amicus Therapeutics
FOLD
$10.7M 1.12%
4,622,230
– –
QLTI
21
DELISTED
QLT Inc
QLTI
$9.5M 1%
2,052,411
+101,775
+5% +$442K
EXAS
22
DELISTED
Exact Sciences
EXAS
$9.2M 0.96%
+779,876
New +$10M
AVEO
23
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$7.23M 0.76%
350,921
– –
SVNT
24
DELISTED
SAVIENT PHARMACEUTICALS INC
SVNT
$5.46M 0.57%
8,752,981
-991,852
-10% -$635K
INSM icon
25
Insmed
INSM
$28.6B
$4.16M 0.44%
266,299
– –
1
2

Similar funds

RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
GPSPJS
General Pension Society PZU Joint Stock Warsaw, Poland $654M AUM 55.85% 1-Year Est. Return
W
WPWealth Fort Worth, Texas $654M AUM 13.19% 1-Year Est. Return
DAS
Diversify Advisory Services Sandy, Utah $655M AUM 24.57% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
SCM
Stevens Capital Management Radnor, Pennsylvania $649M AUM 27.37% 1-Year Est. Return

Palo Alto Investors's Q3 2013 Portfolio in Review

As of Q3 2013, Palo Alto Investors held 36 positions worth $954M, up 13% from $847M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Palo Alto Investors withdrew a net $48.6M in Q3 2013, closing 2 positions and reducing 10 holdings. Its most notable exit was Aegerion Pharmaceuticals, an estimated $3.11M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 36% of assets, up from 34% a quarter earlier.

Against the trend, Palo Alto Investors opened a new position in Exact Sciences worth $9.2M.

  • Palo Alto Investors's largest Q3 2013 buy was Exact Sciences: 779,876 shares worth $9.2M.
  • Palo Alto Investors added most to AUXILIUM PHARAMCEUTICALS INC in Q3 2013, an estimated $31M increase.
  • Palo Alto Investors's biggest Q3 2013 reduction was ONYX PHARMACEUTICALS INC, cutting an estimated $124M.
  • Palo Alto Investors fully exited Aegerion Pharmaceuticals in Q3 2013, selling an estimated $3.11M.
  • Palo Alto Investors's ten largest holdings make up 72% of its $954M portfolio in Q3 2013.
  • Palo Alto Investors opened 4 new positions and closed 2 in Q3 2013.
  • Palo Alto Investors's portfolio value rose 13% quarter-over-quarter to $954M.

Based on Palo Alto Investors's 13F filing for Q3 2013, filed 13 Nov 2013.